TD Cowen analyst Charles Rhyee raised the firm’s price target on Amwell (AMWL) to $8 from $5 and keeps a Hold rating on the shares. The firm said the company beat on both Subscription revenue and Visits revenue and the company raised 2026 EBITDA guidance and set 2Q EBITDA guide above conensus.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AMWL:
- Amwell Maintains Hold as Analyst Lifts Price Target to $6.50 Amid Improving Metrics but Unproven Growth Recovery
- American Well Kept at Hold as Strong Q1 and Profit Progress Offset by Cautious Revenue Outlook and Government Contract Uncertainty
- American Well announces planned board transition for 2026